Oxford BioDynamics (GB:OBD) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Oxford BioDynamics Plc has reported continued growth in its biotechnology segment with an emphasis on the commercialization of its EpiSwitch tests, observing a revenue increase and expanding market presence through various commercial agreements. Despite an operating loss, the company has successfully secured funding to support near-term plans and has advanced its test offerings, including securing US reimbursement for its EpiSwitch PSE test and partnering with health providers for broader access.
For further insights into GB:OBD stock, check out TipRanks’ Stock Analysis page.
